BioCentury | Nov 17, 2017
Clinical News

RedHill's Bekinda meets in Phase II for IBS-D

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) reported top-line data from a Phase II trial in 126 patients with irritable bowel syndrome with diarrhea (IBS-D) showing that once-daily 12 mg oral Bekinda ondansetron met the primary...
BioCentury | Jul 8, 2017

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BioCentury | Jun 30, 2017
Clinical News

RedHill's Bekinda meets in Phase III gastroenteritis trial

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) reported top-line data from the Phase III GUARD trial in 321 patients ages >12 with acute gastroenteritis and gastritis showing that once-daily oral 24 mg Bekinda ondansetron (RHB-102) met...
BioCentury | Apr 7, 2017

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...
BioCentury | Feb 16, 2017
Clinical News

Bekinda: Completed Ph III GUARD enrollment

RedHill completed enrollment of 320 patients in the double-blind, placebo-controlled, U.S. Phase III GUARD trial of 24 mg oral Bekinda (see BioCentury, Oct. 26, 2015 ). RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL), Tel Aviv, Israel...
BioCentury | Dec 31, 2016

Delivering takeouts

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking...
BioCentury | Oct 3, 2016

Combo deals

Allergan plc's two NASH acquisitions give it the second biggest pipeline for the indication and enough mechanisms to develop in-house combinations that could target multiple drivers of the disease pathophysiology. Together, Allergan's Sept. 20 deals...
BioCentury | Jul 11, 2016

Rethinking risk

Steve Edelson, Senior Editor The second half does not contain the high-impact, sector-moving milestones seen in the first six months of the year, but investors still have at least 90 late-stage milestones from which to...
BioCentury | Apr 18, 2016
Clinical News

Bekinda Ondansetron: Phase II started

RedHill began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 12 mg oral Bekinda once daily for 8 weeks in about 120 patients. RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL), Tel Aviv, Israel Product: Bekinda...
BioCentury | Jan 11, 2016

Sowing season

Stephen Hansen, Associate Editor BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This...
Items per page:
1 - 10 of 151